Screener
Arcus Biosciences RCUS EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's EBITDA?
- Arcus Biosciences (RCUS) reported EBITDA of -$93M in Q2 2026.
- How has Arcus Biosciences's EBITDA changed year-over-year?
- Arcus Biosciences's EBITDA decreased by 1450.0% year-over-year, from -$6M to -$93M.
- What is the long-term trend for Arcus Biosciences's EBITDA?
- Over 4 years (2021 to 2025), Arcus Biosciences's EBITDA has grown at a 59.6% compound annual growth rate (CAGR), from $58M to -$376M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Arcus Biosciences's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude